A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
This is an open-label, Phase 2, multicenter study to evaluate the efficacy, safety,
tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination
with balstilimab or standard-of-care treatments in participants with refractory metastati...
Age: 18 years - 66+
Gender: All
A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
The main aims of this study is to test for any side effects from modakafusp alfa in
combination therapy and to determine the recommended dose of combination therapy with
modakafusp. The dose of modakafusp alfa will be increased a little at a time until the
highest...
Age: 18 years - 66+
Gender: All
Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases
This is a phase I, open label study employing diphencyprone (DPCP) to characterize gene expression changes of various immune cell and tumor markers in cutaneous metastases treated with topical DPCP twice weekly for 12 weeks in combination with PD-1 or PD-L1 immune check...
Age: 18 years - 66+
Gender: All
Phase 2 Study of DKN-01 in Colorectal Cancer
This is a Phase 2 randomized, open-label, two-part, multicenter study with a safety run-in to evaluate efficacy and safety of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus standard of care (SOC) [FOLFIRI/FOLFOX and bevacizumab] as second-line treatment of advanced C...
Age: 18 years - 66+
Gender: All
Intestinal Microbiome, Oral Microbiome, and Whole Blood Transcriptome Analyses in Gastrointestinal Malignancies
The primary objective of this prospective observational study is to characterize the gut and
oral microbiome as well as the whole blood transcriptome in gastrointestinal cancer patients
and correlate these findings with cancer type, treatment efficacy and toxicity.
Age: 18 years - 66+
Gender: All
A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery
This study is open to people with newly diagnosed colorectal cancer. People who are scheduled
for surgery can participate. People either get a medicine called BI 765063 combined with
ezabenlimab or combined with pembrolizumab in preparation of the upcoming surgery. ...
Age: 18 years - 66+
Gender: All
Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma
This study is a first-in-human, Phase 1/2, open label study that will evaluate safety and
efficacy of ISB 1442 in relapsed/refractory multiple myeloma (R/R MM).
Age: 18 years - 66+
Gender: All
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in
participants with PSMA-expressing metastatic castrate resistant prostate cancer.
Age: 18 years - 66+
Gender: Male
Pembrolizumab in MIBC
Subjects with cT2-T3N0M0 urothelial cancer of the bladder will be enrolled. After completing
two cycles of pembrolizumab, subjects will undergo a restaging MRI of the abdomen and pelvis
with a standard acquisition protocol (as outlined in the protocol) as well as CT...
Age: 18 years - 66+
Gender: All
A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma
The purpose of this study is to evaluate the efficacy and safety of cilta-cel
out-of-specification (OOS).
Age: 18 years - 66+
Gender: All
A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
The purpose of the study is to identify the safe dose(s) of a PD-1 inhibitor in combination
with talquetamab or teclistamab, and to characterize the safety and tolerability of
talquetamab or teclistamab when administered in combination with a PD-1 inhibitor.
Age: 18 years - 66+
Gender: All
Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy
The number of elderly head-and-neck squamous cell carcinoma (HNSCC) patients is increasing;
however, the evidence regarding the ideal treatment for this often vulnerable and frail
patient cohort is limited. Although the benefit of concomitant chemotherapy has been r...
Age: 65 years - 66+
Gender: All
Pilot Trial of Colchicine in Urothelial Cancer and Other Solid Tumors
This open-label, non-randomized study aims to determine the anti-inflammatory effect of colchicine on the reduction of peripheral blood CRP in patients with solid tumors or localized urothelial cancer. There are two cohorts, which will enroll separately and parallelly. ...
Age: 18 years - 66+
Gender: All
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of
IMP9064 as monotherapy or in combination with PARP inhibitor Senaparib in patients with
advanced solid tumors
Age: 18 years - 66+
Gender: All
A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer
This is an open-label, multicenter, dose-escalation study designed to assess the safety,
tolerability, and PK of IV administered DAN-222 followed by a dose-escalation of DAN-222 in
combination with niraparib. There are two stages within this study:
Stage 1:
...
Age: 18 years - 66+
Gender: Female
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
This phase III trial compares the effect of open thoracic surgery (thoracotomy) to
thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients
with osteosarcoma that has spread to the lung (pulmonary metastases). Open thoracic surgery
...
Age: Birth - 50 years
Gender: All
A Study of hSTC810 With Advanced/Metastatic Solid Tumors (STCUBE-001)
The Purpose of this study is to investigate the safety, tolerability, pharmacokinetics, and
preliminary efficacy of hSTC810 monotherapy in participants with advanced solid tumors.
Age: 18 years - 66+
Gender: All
Rectal Spacer Hydrogel Before Radiation Therapy in Reducing Radiation Dose to the Rectum in Patients With Prostate Cancer
This phase II trial studies the effect of rectal spacer hydrogel before radiation therapy in reducing radiation dose to the rectum in patients with prostate cancer. Rectal spacer hydrogen is a soft gel material used to create a space between the rectum and prostate duri...
Age: 18 years - 66+
Gender: Male
Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies
This is an open-label, prospective phase two basket trial assessing the efficacy of
ulixertinib in combination with hydroxychloroquine in patients with advanced gastrointestinal
malignancies. All patients enrolled must have a mitogen-activated protein kinase (MAPK)
...
Age: 18 years - 66+
Gender: All
Screening Women With Prior HPV for Anal Neoplasia
The goal of this single arm trial is to prospectively evaluate screening methods for anal
cancer precursors in HIV uninfected women with a history of lower genital tract neoplasias
and cancers.
Age: 45 years - 66+
Gender: Female